Table 1.

Efficacy of systemic targeted monotherapy in hepatocellular carcinoma according to current phase I-III studies

Author	Year	Phase	Investigational drug	n	RR	DS	PFS/TTP	PFS-6m	OS
O'Neil et al[59]¹	2009	II	AZD 6244	16	0	37.5	NR	NR	NR
Malka et al[60]	2007	II	Bevacizumab	30	12.5	54	3.5/NR	17	NR
Schwartz et al[61]	2006	II	Bevacizumab	30	6.7	57	NR/6.4	NR	NR
Siegel et al[58]	2008	II	Bevacizumab	46	13	NR	6.9/NR	NR	12.4
Raoul et al[62]	2009	II	Brivanib	55	11	10	NR/2.8	NR	10
Gruenwald et al[63]	2007	II	Cetuximab	27	0	44	2.0/1.9	22.2	NR
Zhu et al[64]	2007	II	Cetuximab	30	0	17	1.4/NR	NR	9.6
Philip et al[65]	2005	II	Erlotinib	38	9	50	3.2/NR	32	13
Thomas et al[66]	2007	II	Erlotinib	40	0	43	3.1/NR	NR	6.25 (10.75)²
Blaszkowsky et al[67]	2010	III	Everolimus	25	4	44	3.8/3.9	8%	8.4
O’Dwyer et al[68]	2006	II	Gefitinib	31	3	22.5	2.8/NR	NR	6.5
Lin et al[69]	2008	II	Imatinib	15	0	13.3	NR/NR	NR	NR
Ramanathan et al[70]	2006	II	Lapatinib	37	5	35	2.3/NR	2.3	6.2
Rizell et al[71]	2008	II	Sirolimus	21	4.8	23.8	NR/NR	NR	6.5
Abou-Alfa et al[12]	2006	II	Sorafenib	137	2.2	33.6	NR/4.2	NR	9.2
Cheng et al[72]	2009	III	Sorafenib	226 (150 treated)	3.3	54	NR/2.8	NR	6.5
Furuse et al[13]	2008	I	Sorafenib	27	4	83	NR/4.9	46.2	15.6
Llovet et al[11]	2008	III	Sorafenib	602 (299 treated)	2	71	NR/5.5	NR	10.7
Yau et al[14]	2009	II	Sorafenib	51	8	18	3.0/NR	NR	5
Zhu et al[73]	2009	II	Sunitinib	34	2.9	47	3.9/4.1	NR	9.8
Faivre et al[74]	2009	II	Sunitinib	37	2.7	35	3.7/5.3	NR	8
Hoda et al[75]	2008	II	Sunitinib	23	6	35	NR/NR	NR	NR
Koeberle et al[54]	2010	II	Sunitinib	45	2	40	2.8/2.8	NR	9.3
Kanai et al[57]	2010	I/II	TSU-68	35	8.6	42.8	NR/2.1	NR	13.1

¹Trial stopped;

Recorded from therapy start (recorded from diagnosis). DS: Disease stabilization (%); NR: Not reported; OS: Overall survival (mo); PFS/TTP: Progression free survival/time to progression (mo); PFS-6m: Progression free survival rate at 6 mo (%); RR: Response rate [complete + partial response (%)].